Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Breast

This is a phase Ib / II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Breast
I/II
Abramson, Vandana
NCT03838367
VICCBREP1983

Galunisertib and Paclitaxel in Treating Patients with Metastatic Androgen Receptor Negative or Triple Negative Breast Cancer

Breast

This phase I trial studies the side effects and best dose of galunisertib when given together with paclitaxel in treating patients with androgen receptor negative or triple negative breast cancer that has spread to other places in the body. Some tumors need growth factors, which are made by the body's white blood cells, to keep growing. Galunisertib may interfere with growth factors and help cause tumor cells to die. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving glunisertib together with paclitaxel may kill more tumor cells.
Breast
I
Abramson, Vandana
NCT02672475
VICCBRE1557

Capecitabine and Radiation Therapy after Surgery in Treating Patients with Non-Metastatic Invasive Breast cancer

Multiple Cancer Types

This phase I trial studies how well capecitabine and radiation therapy after surgery work in treating patients with invasive breast cancer that has not spread to other places in the body. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving capecitabine and radiation therapy together may kill more tumor cells in patients with invasive breast cancer compared to capecitabine or radiation therapy alone.
Breast, Phase I
I
Chak, Bapsi
NCT03958721
VICCBREP1898

Ketogenic Diet with Letrozole in Treating Patients with Estrogen Receptor Positive Breast Cancer

Breast

This early phase I trial studies how well ketogenic diet with letrozole works in treating patients with estrogen receptor positive breast cancer. Estrogen receptor positive breast cancer has special proteins on it, called estrogen receptors, that allow it to grow when exposed to estrogen. A ketogenic diet (low calorie, low carbohydrate) may help normalize abnormally high insulin levels that in turn may slow the growth of cancer cells. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.The purpose of this study is to learn if the combination of a 2 week ketogenic diet in combination with letrozole can help slow the growth of tumors.
Breast
Early I
Rexer, Brent
NCT03962647
VICCBRE18108

A Computerized Program (Neuroplasticity-Based Cognitive Remediation) for the Treatment of Chemotherapy Related Cognitive Impairment in Patients with Breast, Colon, Lymphoma, or Ovarian Cancer

Multiple Cancer Types

This trial studies how well a computerized program called neuroplasticity-based cognitive remediation works for the treatment of chemotherapy related cognitive impairment in patients with breast, colon, lymphoma, or ovarian cancer. There are few if any treatments shown to be effective in improving thinking and functioning in patients with attention and memory problems related to cancer treatment. This may leave patients vulnerable to loss of independence and functioning, and to developing depressive symptoms. Neuroplasticity-based cognitive remediation may help to improve thinking, functioning, and depressive symptoms in patients with breast, colon, lymphoma, or ovarian cancer.
Breast, Colon, Lymphoma, Ovarian
N/A
Newhouse, Paul
NCT04230863
VICCSUPP1936

Fluid Measurements and MRI in Determining Biomarkers of Lymphatic Dysfunction in Patients with Breast Cancer

Breast

This trial uses fluid measurements of the arm and MRI to determine biomarkers of lymphatic dysfunction in patients with breast cancer. Studying the lymphatic system (the part of your body that helps to process and clear waste products) in different ways will help doctors understand more about lymphedema (excess fluid after lymph nodes are removed) and help with prevention and management of lymphedema in patients with breast cancer.
Breast
N/A
Donahue, Manus
NCT03760744
VICCBRE18156

Ruxolitinib in Preventing Breast Cancer in Patients with High Risk and Precancerous Breast Lesions

Breast

This phase II trial studies how well ruxolitinib before surgery works in preventing breast cancer in patients with high risk and precancerous breast conditions. Ruxolitinib may changes the breast cell when administered to participants with precancerous breast conditions. Ruxolitinib may stop the growth of cells by blocking some of the enzymes needed for cell growth.
Breast
II
Meszoely, Ingrid
NCT02928978
VICCBRE1904

Breast Tissue/Body Fluids Repository (SPORE)

Breast

Breast
N/A
Chak, Bapsi
NCT00899301
VICCBRE03103

Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Breast

This trial collects clinical information and tissue and blood samples from patients with breast cancer that has come back or is stage IV. Collecting clinical information and biospecimen samples to create a registry may help doctors better understand the mechanism of tumor spread and determine why people respond differently to specific cancer treatments.
Breast
N/A
Park, Ben
NCT03737695
VICCBRE1954

Study of IMMU-132 in HR+ / HER2- MBC (TROPICS-02)

Breast

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+ / HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.
Breast
III
Mayer, Ingrid
NCT03901339
VICCBRE1942

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: